| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
BR-1 targets PRL-3 (phosphatase of regenerating liver-3), also known as PTP4A3, a protein tyrosine phosphatase that plays critical roles in cell proliferation, motility, and invasion, and thus contributes to cancer metastasis. BR-1 is a selective inhibitor of PRL-3 with an IC50 of 0.9 µM. It shows minimal activity against other phosphatases, indicating good selectivity. By inhibiting PRL-3, BR-1 prevents the migration and invasion of metastatic cancer cells.
|
|---|---|
| ln Vitro |
In a cell-based experiment, PRL-3 Inhibitor I (compound 5e) lowers the sensitivity of mouse melanoma B16F10 cells [1].
In vitro, BR-1 is a potent and selective inhibitor of PRL-3 with an IC50 of 0.9 µM. It shows minimal activity against other phosphatases. BR-1 inhibits the migration and invasion of metastatic cancer cells. Its activity is characterized by its ability to block PRL-3-driven motility without causing cytotoxicity. The compound's selectivity for PRL-3 over other phosphatases makes it a valuable tool for studying the role of PRL-3 in cancer metastasis. |
| ln Vivo |
Specific in vivo activity data for BR-1 is not detailed in the provided search results. As a PRL-3 inhibitor, it would be evaluated in animal models of cancer metastasis. The compound's ability to inhibit tumor cell migration and invasion suggests it could reduce metastatic spread in vivo. Further studies are needed to characterize its in vivo efficacy, pharmacokinetics, and safety profile.
|
| Enzyme Assay |
The in vitro activity of BR-1 is assessed using cell-free phosphatase activity assays. Recombinant PRL-3 is incubated with a fluorogenic or chromogenic phosphatase substrate in the presence of varying concentrations of BR-1. The dephosphorylation of the substrate is measured spectrophotometrically or fluorometrically. The IC50 is determined from dose-response curves. For selectivity profiling, the compound is tested against a panel of other phosphatases (including other PRL family members, PTP1B, etc.) to assess its specificity for PRL-3.
|
| Cell Assay |
For cellular assays, metastatic cancer cell lines (e.g., breast, colon, or prostate cancer cells) are cultured in appropriate media. Cells are treated with various concentrations of BR-1 (typically 0.1-100 µM) for defined periods (24-72 hours). Cell migration and invasion are assessed using Transwell chambers or scratch wound healing assays. Cell viability is assessed using MTT or CellTiter-Glo assays. The activity of PRL-3 in treated cells can be assessed by measuring its phosphatase activity in cell lysates using a suitable substrate.
|
| Animal Protocol |
In vivo, BR-1 would be administered to mice bearing metastatic tumor models. The compound is formulated in a suitable vehicle (e.g., 5% DMSO, 40% PEG300, 5% Tween-80, and 50% ddH2O) and administered at various doses via intraperitoneal or oral routes. Tumor growth and metastasis are monitored by imaging or by assessing tumor burden in target organs. The effects on tumor cell migration and invasion are evaluated by histopathological examination of metastatic lesions.
|
| ADME/Pharmacokinetics |
BR-1 has a molecular weight of 485.21 g/mol and a molecular formula of C17H11Br2NO2S2. It is a cell-permeable compound that is soluble in DMSO. The compound should be stored as a powder at -20°C under desiccated conditions. Specific pharmacokinetic parameters such as bioavailability, half-life, and volume of distribution are not detailed in the provided search results.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for BR-1 is not available in the provided search results. As a PRL-3 inhibitor, it may affect normal cell migration and invasion processes, which are important for wound healing and immune cell function. The compound is intended for research purposes only and is not approved for human or veterinary use. Standard laboratory safety precautions should be followed when handling the compound. Comprehensive toxicological studies are required to establish its full safety profile.
|
| References | |
| Additional Infomation |
5-[[5-bromo-2-[(2-bromophenyl)methoxy]phenyl]methylene]-2-thiomethylene-1,3-thiazolidin-4-one is an aromatic ether.
BR-1 is a research compound that has been developed as a selective PRL-3 inhibitor for the study of cancer metastasis. PRL-3 is a protein tyrosine phosphatase that is overexpressed in various cancers and is associated with metastatic progression. BR-1's ability to inhibit PRL-3 activity and block cancer cell migration and invasion makes it a valuable tool for studying the mechanisms of metastasis. BR-1 is not approved for clinical use and is intended for research purposes only. It is available from chemical suppliers for research applications. |
| Molecular Formula |
C17H11BR2NO2S2
|
|---|---|
| Molecular Weight |
485.21
|
| Exact Mass |
482.86
|
| CAS # |
893449-38-2
|
| PubChem CID |
11983303
|
| Appearance |
Light yellow to green yellow solid powder
|
| LogP |
5.608
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
24
|
| Complexity |
529
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C(C(=C1)COC2=C(C=C(C=C2)Br)/C=C\3/C(=O)NC(=S)S3)Br
|
| InChi Key |
HXNBAOLVPAWYLT-NVNXTCNLSA-N
|
| InChi Code |
InChI=1S/C17H11Br2NO2S2/c18-12-5-6-14(22-9-10-3-1-2-4-13(10)19)11(7-12)8-15-16(21)20-17(23)24-15/h1-8H,9H2,(H,20,21,23)/b15-8-
|
| Chemical Name |
(5Z)-5-[[5-bromo-2-[(2-bromophenyl)methoxy]phenyl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one
|
| Synonyms |
BR-1 BR 1 BR1
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~41.67 mg/mL (~85.88 mM)
H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0610 mL | 10.3048 mL | 20.6096 mL | |
| 5 mM | 0.4122 mL | 2.0610 mL | 4.1219 mL | |
| 10 mM | 0.2061 mL | 1.0305 mL | 2.0610 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
